SOLICITATION NOTICE
B -- Norgen RNA Isolation from urine samples
- Notice Date
- 8/25/2016
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2016-291-DM
- Archive Date
- 9/15/2016
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Heart, Lung, and Blood Institute (NHLBI) and the National Human Genome Research Institute (NHGRI), intends to negotiate and award a purchase order on a non-competitive sole source basis to Norgen Biotek Corp., 3430 Schmon Parkway, Thorold, ON L2V 4Y6 Canada to procure the following: Procurement: 1. RNA Isolation from urine samples, Spike in control cel-mir39 (NGS grade) QC of extracted RNA, Quantity: 240; and 2. Sample Amplification & Library Preparation, Library QC, Small RNA-Seq (Illumina Platform), Bioinformatics Analysis; Quantity: 240. Period of Performance : 12-Months Upon Award Background: The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The Gibbons Laboratory administratively housed within NHGRI's Division of Intramural Research, conducts a wide portfolio of clinical research addressing the issue of minority health disparities, especially as they pertain to cardiovascular disease. The NHGRI/DIR Cardiovascular Disease Section (CDS), Gibbons Laboratory conducts a broad program of clinical and translational research seeking a greater understanding of the genomic basis of human cardiovascular disease. A major component of research centers on understanding transcriptome changes contributing to cardiovascular disease phenotypes such as resistant hypertension and coronary calcification. The goals of CDS include identifying transcriptome dysregulation in microRNAs contained in the above samples that contribute to cardiovascular disease endpoints such as resistant hypertension. Purpose and Objectives : miRNAs are an important class of biological molecules between 18-22 nucleotides in length which perform crucial functions in gene regulation through mechanisms such as knockdown of antisense transcripts. Recently, it has become possible to profile the comprehensive set of miRNAs in a sample through a method known as miRNA-Seq, based on Illumina chemistry for next-generation DNA sequencing. Exosomes are nanoparticles secreted into the extracellular spaces of human organ systems that are being recently recognized and containing crucial information in the form of their protein and RNA cargo. However, due to their small size and the extremely small quantities present, it requires personnel with high levels of training and expertise to be able to isolate exosomes and the RNA within them. The NHGRI-NHLBI Gibbons lab currently possesses human urine samples from cases and controls for resistant hypertension, a cardiovascular disease phenotype. At the time of collection, these samples were treated with Norgen Urine Preservative, a reagent specifically designed to maintain DNA and RNA in pristine condition. The Gibbons lab is currently archiving in our cryorepository human urine samples from cases and controls for resistant hypertension, a cardiovascular disease phenotype. As part of this research, researchers intend to investigate transcriptional changes associated with such phenotypes in exosomes using miRNA-Seq. The current service being requested is to extract exosomal RNA from these samples that were earlier treated with Norgen preservative. Regulatory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source and is not expected to exceed the simplified acquisition threshold, only one responsible source and no other supplies or services will satisfy agency requirements. This requirement is under the SAT of $150,000.00. Statutory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Closing Statement : Industry Classification (NAICS) Code is 541711 Research and Development in Biotechnology and the small business size standard is 1000. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2005-89-1 (August 15, 2016). This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by August 31, 2016 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2016-291-DM, ny 7:30 a.m. Eastern time and may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell, Contracting Officer. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2016-291-DM/listing.html)
- Record
- SN04241329-W 20160827/160825235837-e3c5c06c5d1b23c53a5d62d5258cfc37 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |